As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: August 31, 2012
by Medical XPress:
A compound developed to treat neuropathic pain has shown potential as an innovative treatment for Alzheimer’s disease, according to a study by researchers at Cleveland Clinic’s Lerner Research Institute and Anesthesiology Institute.
“Cleveland Clinic dedicated two years of research into the examination of this compound and our findings show it could represent a novel therapeutic target in the treatment of Alzheimer’s disease,” said Mohamed Naguib, M.D., Professor of Anesthesiology, Cleveland Clinic Lerner College of Medicine. “Development of this compound as a potential drug for Alzheimer’s would take many more years, but this is a promising finding worthy of further investigation.”
In a study published online in the Neurobiology of Aging, the compound MDA7 induced beneficial immune responses that limited the development of Alzheimer’s disease. Treatment with the compound restored cognition, memory and synaptic plasticity – a key neurological foundation of learning and memory – in an animal model.
Neuroinflammation is an important mechanism involved in the progression of Alzheimer’s disease. The MDA7 compound has anti-inflammatory properties that act on the CB2 receptor – one of the two cannabinoid receptors in the body – but without the negative side effects normally seen with cannabinoid compounds.
Alzheimer’s disease is an irreversible, fatal brain disease that slowly destroys memory and thinking skills. About 5 million people in the United States have Alzheimer’s disease. With the aging of the population, and without successful treatment, there will be 16 million Americans and 106 million people worldwide with Alzheimer’s by 2050, according to the 2011 Alzheimer’s Disease Facts and Figures report from the Alzheimer’s Association.
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
Foods can determine whether someone will suffer from dementia in later years, according to researchers at the Hebrew University of Jerusalem’s Faculty of Agriculture, Food and Environment in Rehovot. A large-scale international study that...
Taking care of someone with Alzheimer’s disease and other forms of dementia is not an easy task. Caregiving is a long-term endeavour that is mentally, emotionally, physically, and financially demanding, and is a role that...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.